Leading Pharmaceutical Suppliers in India for Generics

India is one of the world’s largest providers of generic medicines. It supplies 50% of the world’s vaccine demand and 40% of drug requirements in the US.

It produces a variety of generic drugs including anti-infective, gastroenterology and pain management medications. It also manufactures a variety of APIs. JCPL is well known for its acetaminophen products that help relieve pain and fever.

Medsexporter Pharma

Medsexporter Pharma is a pharmaceutical company that specializes in research, manufacture and marketing of quality finished dosages. Its products are primarily focused on branded generic drugs in India and in emerging markets of Asia. Its products include drugs for cardiovascular diseases, ophthalmology, and dermatology and pain management. Its drugs are available in many different forms, including tablets, creams and injections.

Founded in 2008 Medsexporter Pharma is based in Surat, India and has presence across the globe. Its business includes Branded Generics in India & Emerging Markets and Generic business in USA. Its brands hold leadership positions in sub-therapeutic areas of cardiology, ophthalmology, and dermatology. In addition, it offers anti-malarial, antibiotics, and multivitamins to its customers.

The company has seven manufacturing facilities across India. Six of the plants produce finished formulations, including two that are USFDA approved. The company also has an advanced R&D center for both finished and API synthesis of various dosage forms.

Medsexporter Pharma has a workforce of about 8,500 employees worldwide. The company has a strong focus on establishing and expanding its international sales network. Its products are sold in more than 30 countries around the world. Its branded generics and specialty therapies are in demand in many developed and emerging countries.

Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories is an Indian pharmaceutical company that manufactures many of the generic drugs sold in the United States. It also performs contract manufacturing for some brand-name drugs. In recent years, the company has diversified into biosimilars and other specialty products. The company has a large presence in the US, Europe, Russia and India. In addition, it has a significant active pharmaceutical ingredients business.

In November, the FDA issued a warning letter to three of Dr. Reddy’s facilities for violations of current good manufacturing practices. The company claims the violations are mostly procedural and have no implication on its quality controls. However, the FDA will not allow the company to begin new drug applications until the violations are corrected.

Reddy’s has entered into a 10-year agreement with Rheoscience A/S of Denmark for the joint development and commercialization of balaglitazone, a novel treatment for type-2 diabetes. The deal is expected to be completed in 2022. In addition to this, the company has formed Perlucin Pharma Pvt Ltd together with ICICI Ventures Fund Management Company Ltd and Citigroup Venture Capital International Growth Partnership Mauritius Ltd to undertake clinical development and out-licensing of new chemical entities.

The company is pursuing low-cost innovation in NCEs and other proprietary products, with an emphasis on dermatology and neurology. In addition, the company has a strategic alliance with Merck Serrano for monoclonal antibodies. Its recent acquisition of Triteness Therapeutics Inc provided access to a pipeline of proprietary products in the US.

The work culture at Dr Reddy’s is rated 4.1 by employees on Ambition Box. It offers a good work-life balance, remuneration and career growth. Moreover, it provides flexible working arrangements and has an attractive bonus plan for high performers.

Cipla

The company is known for its AIDS and flu drugs. It also manufactures other medicines, including those for respiratory and cardiovascular diseases. Its products are sold in more than 100 countries worldwide. The company also provides services like pharmacovigilance, clinical trials, and market research. Its research center is located near Pune, India. Its product portfolio includes complex generics and pharmaceutical ingredients.

Founded in 1935 as Chemical Industrial & Pharmaceutical Laboratories Ltd, the company changed its name to Cipla in 1984. Its corporate headquarters is located in Mumbai, India. The company has more than 47 manufacturing sites worldwide. The company also offers biosimilars, consumer health products, and respiratory medicines. Its products are sold in more than 65 therapeutic categories.

In recent years, the company has expanded its footprint in Africa and South America. The company has also diversified its operations by investing in biotechnology companies. It has a presence in the US through its subsidiary Exelon Pharmaceuticals. Its products include anti-diarrheal agents and antibiotics, antacids, and cough and cold medicines.

Cipla has been a leader in developing new medicines, especially for HIV and the flu. Its success has led to interest from private equity players. The company is still a family-owned enterprise, but its future remains unclear. While it has a strong balance sheet, Cipla’s growth could be limited by government regulation and the need to invest in infrastructure. It may also face competition from generics producers in other countries. The company has a good reputation for delivering quality products at affordable prices.

Eurobond Pharma Industries

The company is a leading pharmaceutical supplier in India for generics, with an extensive portfolio of over 290 medicines. Its core areas of activity include central nervous system, anti-retroviral, cardiovascular, and gastrointestinal products. It also specializes in developing innovative drug delivery solutions, such as depot injections and inhalers. The company’s products are sold in over 155 countries around the world.

Eurobond Pharma’s research and development capabilities are focused on developing intellectual property in non-infringing processes and solving complex chemistry challenges. The company’s R&D center in Hyderabad covers over 13,000 sq. m and provides a nurturing environment for more than 700 scientists. It has a strong track record of innovation and is highly profitable.

The company’s manufacturing capacity includes four facilities in the US for APIs, 13 plants in India, and one facility in Brazil. In addition, the company has an integrated supply chain that includes a network of distributors and wholesalers. This allows Eurobond to deliver the right product at the right time and place.

Eurobond has a Day-1 generic policy, which means that it will launch a generic version of a brand-name medicine as soon as the patent expires in the EU and the US. This helps to reduce prices and increase accessibility for patients. In addition, the company’s generic antibiotics have high efficacy and safety profiles.

Using Blind, you can evaluate Eurobond Pharma Ltd.’s clinical operations, recruitment, and trial strategy. This helps you stay competitive and improve corporate planning. You can also anticipate future catalyst impacts and determine the best opportunities to strengthen your business development efforts.